Council Decision of 13 June 2022 appointing four members of the Management Board of the European Medicines Agency2022/C 233/04

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency⁽¹⁾, and in particular Article 65(1) thereof,

Having regard to the list of candidates submitted to the Council by the European Commission on 27 January 2022,

Having regard to the views expressed by the European Parliament by letter dated 24 May 2022,

Whereas:

1. Pursuant to Article 65(4) of Regulation (EC) 726/2004, the term of office of the members of the Management Board of the European Medicines Agency (‘Management Board’) currently in office will expire on 14 June 2022. The members of the Management Board whose term of office is to start on 15 June 2022 are to be appointed in accordance with the procedure for nomination and appointment laid down in Regulation (EC) 726/2004.

2. Article 65(1) of Regulation (EC) No 726/2004 requires that the Management Board also include two representatives of patients’ organisations, one representative of doctors’ organisations and one representative of veterinarians’ organisations.

3. Those members are to be appointed by the Council in consultation with the European Parliament on the basis of a list drawn up by the Commission which is to include appreciably more names than there are posts to be filled. Their term of office is to be three years and can be renewed.

4. The Commission has drawn up and submitted a list of candidates to the Council on 27 January 2022. The candidates included in the list submitted by the Commission have been selected following a call for expression of interest and on the basis of their specialist qualifications, their broad spectrum of relevant expertise as well as their relevant expertise in management and experience in the field of medicinal products for human or veterinary use.

5. The list submitted by the Commission has been examined with a view to appointing the four members of the Management Board representing civil society on the basis of the documentation provided by the Commission and in light of the views expressed by the European Parliament. The appointment of those members, by means of this Decision, further secures that the highest levels of specialist qualifications, a broad spectrum of relevant expertise and the broadest possible geographic spread within the Union, as well as relevant expertise in management and experience in the field of medicinal products for human or veterinary use, is available within the Management Board,

HAS ADOPTED THIS DECISION: